Logo image of WHWK

WHITEHAWK THERAPEUTICS INC (WHWK) Stock Fundamental Analysis

NASDAQ:WHWK - Nasdaq - US00032Q1040 - Common Stock - Currency: USD

1.88  +0.02 (+1.08%)

Fundamental Rating

4

WHWK gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. While WHWK has a great health rating, there are worries on its profitability. WHWK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

WHWK had negative earnings in the past year.
In the past year WHWK has reported a negative cash flow from operations.
WHWK had negative earnings in each of the past 5 years.
WHWK had a negative operating cash flow in each of the past 5 years.
WHWK Yearly Net Income VS EBIT VS OCF VS FCFWHWK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

WHWK has a better Return On Assets (11.80%) than 95.14% of its industry peers.
WHWK's Return On Equity of 12.45% is amongst the best of the industry. WHWK outperforms 94.59% of its industry peers.
Industry RankSector Rank
ROA 11.8%
ROE 12.45%
ROIC N/A
ROA(3y)-57.7%
ROA(5y)-50.49%
ROE(3y)-74.03%
ROE(5y)-62.56%
ROIC(3y)N/A
ROIC(5y)N/A
WHWK Yearly ROA, ROE, ROICWHWK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K

1.3 Margins

WHWK's Profit Margin of 99.42% is amongst the best of the industry. WHWK outperforms 99.28% of its industry peers.
The Gross Margin of WHWK (88.72%) is better than 91.17% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 99.42%
GM 88.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WHWK Yearly Profit, Operating, Gross MarginsWHWK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

8

2. Health

2.1 Basic Checks

WHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, WHWK has more shares outstanding
Compared to 5 years ago, WHWK has more shares outstanding
WHWK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
WHWK Yearly Shares OutstandingWHWK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
WHWK Yearly Total Debt VS Total AssetsWHWK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

WHWK has an Altman-Z score of 3.13. This indicates that WHWK is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of WHWK (3.13) is better than 73.51% of its industry peers.
There is no outstanding debt for WHWK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.13
ROIC/WACCN/A
WACC8.93%
WHWK Yearly LT Debt VS Equity VS FCFWHWK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

WHWK has a Current Ratio of 18.95. This indicates that WHWK is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 18.95, WHWK belongs to the top of the industry, outperforming 92.25% of the companies in the same industry.
A Quick Ratio of 18.95 indicates that WHWK has no problem at all paying its short term obligations.
The Quick ratio of WHWK (18.95) is better than 92.25% of its industry peers.
Industry RankSector Rank
Current Ratio 18.95
Quick Ratio 18.95
WHWK Yearly Current Assets VS Current LiabilitesWHWK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

WHWK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
Looking at the last year, WHWK shows a quite strong growth in Revenue. The Revenue has grown by 16.51% in the last year.
WHWK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 185.21% yearly.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.59%
Revenue 1Y (TTM)16.51%
Revenue growth 3Y185.21%
Revenue growth 5YN/A
Sales Q2Q%33.48%

3.2 Future

WHWK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.21% yearly.
WHWK is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y92.62%
EPS Next 2Y8.71%
EPS Next 3Y5.21%
EPS Next 5YN/A
Revenue Next Year47.36%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
WHWK Yearly Revenue VS EstimatesWHWK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2021 2022 2023 2024 2025 2031 2032 10M 20M 30M
WHWK Yearly EPS VS EstimatesWHWK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WHWK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WHWK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WHWK Price Earnings VS Forward Price EarningsWHWK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WHWK Per share dataWHWK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.71%
EPS Next 3Y5.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for WHWK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WHITEHAWK THERAPEUTICS INC

NASDAQ:WHWK (7/2/2025, 4:30:02 PM)

1.88

+0.02 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners58.8%
Inst Owner ChangeN/A
Ins Owners12.42%
Ins Owner ChangeN/A
Market Cap88.57M
Analysts47.5
Price Target2.04 (8.51%)
Short Float %0.77%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-88.72%
Min EPS beat(2)-198.57%
Max EPS beat(2)21.14%
EPS beat(4)3
Avg EPS beat(4)-38.18%
Min EPS beat(4)-198.57%
Max EPS beat(4)23.27%
EPS beat(8)5
Avg EPS beat(8)-16.77%
EPS beat(12)8
Avg EPS beat(12)-8.77%
EPS beat(16)11
Avg EPS beat(16)-6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)-9.2%
EPS NQ rev (3m)N/A
EPS NY rev (1m)83.33%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)6.91%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.19
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0.59
BVpS4.71
TBVpS4.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.8%
ROE 12.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 99.42%
GM 88.72%
FCFM N/A
ROA(3y)-57.7%
ROA(5y)-50.49%
ROE(3y)-74.03%
ROE(5y)-62.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 733%
Cap/Sales 5.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.95
Quick Ratio 18.95
Altman-Z 3.13
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)1160.76%
Cap/Depr(5y)712.22%
Cap/Sales(3y)8.52%
Cap/Sales(5y)6.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.59%
EPS Next Y92.62%
EPS Next 2Y8.71%
EPS Next 3Y5.21%
EPS Next 5YN/A
Revenue 1Y (TTM)16.51%
Revenue growth 3Y185.21%
Revenue growth 5YN/A
Sales Q2Q%33.48%
Revenue Next Year47.36%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y18.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.45%
OCF growth 3YN/A
OCF growth 5YN/A